Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.61 |
| ▸ | F7 | P08709 | 3/20 | 0.61 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.61 |
| ▸ | F10 | P00742 | 2/20 | 0.61 |
| ▸ | F12 | P00748 | 2/20 | 0.61 |
| ▸ | PLG | P00747 | 1/20 | 0.61 |
| ▸ | KLK1 | P06870 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5106013 | 0.92 | F11 (0.68) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL5106016 | 0.92 | F11 (0.68) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL27692640 | 0.90 | F11 (0.67) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL6404189 | 0.90 | F11 (0.67) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL6404186 | 0.90 | F11 (0.67) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL394684 | 0.90 | F11 (0.74) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL27674024 | 0.90 | F11 (0.74) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL6409535 | 0.90 | F11 (0.74) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL394683 | 0.90 | F11 (0.74) | F11KLKB1F7PRSS1PRSS2 | |
| SCHEMBL6409591 | 0.88 | F11 (0.74) | F11KLKB1F7PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-8101778-B2 | Five-membered heterocycles useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088758-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | F11 2/4885KLKB1 21/4885F7 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.